Tag Archives: NIAID

Challenges in the March Toward an AIDS-Free Generation

By Ben Comer | Published: August 1, 2012
FDA’s approval of Truvada, a once-a-day oral combination of tenofovir and emtricitabine, for pre-exposure prophylaxis (or PrEP, a method for preventing HIV infection) arrived during a chorus of optimism surrounding major developments in the fight against AIDS.
Posted in Biotech, Events, FDA, Market Access, Patient Communication, Regulatory, Safety, healthcare, patient compliance, patient education, pricing | Also tagged , , , , , , | Leave a comment

Industry Optimism for Advancing TB Research

By Guest Blogger | Published: March 21, 2012
Scientists optimistic new combination regimens will improve TB treatment and reduce drug resistance, writes Jill Wechsler, Pharm Exec’s Washington Editor. In honor of World TB Day March 24, research organizations and international health agencies announced important advances in the development of new therapies for stemming the spread of increasingly lethal tuberculosis strains. Each year, nearly 9 [...]
Posted in FDA, Global, Op-Ed, healthcare | Also tagged , , | Leave a comment